GLP-1 drugs

Hims & Hers reports Q1 earnings May 11 after settling patent dispute with Novo Nordisk, gaining rights to sell Wegovy and Ozempic while discontinuing compounded alternatives.

Novo Nordisk's Q1 sales of $15.17B beat estimates, with Wegovy pill reaching 2M prescriptions. Company raised 2026 guidance to $42.39-$46.24B; shares surged 7.11%.

Eli Lilly's 56% revenue growth and 156% EPS surge in Q1 2026, driven by GLP-1 dominance and oral formulation expansion, signal continuing upside potential for investors.

Eli Lilly stock near $960 has 26% upside to $1,215 consensus target, driven by blockbuster GLP-1 drugs Mounjaro and Zepbound delivering 60% revenue growth.

Eli Lilly's weight loss drugs deliver explosive growth with Mounjaro up 125% and Zepbound up 80%. New oral drug Foundayo already serves 20,000 patients.

Pfizer's 50% stock decline masks a 6.4% dividend yield and strategic repositioning in GLP-1 drugs, oncology, and migraine treatments, offering potential upside for patient investors.

Three dividend stocks—Coca-Cola, General Mills, and Hormel Foods—present long-term opportunities for patient investors seeking steady income streams despite near-term industry challenges.

Amazon launches GLP-1 weight management program through One Medical, leveraging its healthcare ecosystem and logistics capabilities to tap into a market projected to reach nearly $100 billion by 2030.

Hims & Hers exploits GLP-1 and estrogen patch shortages, securing steady inventory to position itself as critical pharmaceutical supply anchor amid three-year supply constraints.

Kailera Therapeutics surged 63% on Nasdaq debut as weight-loss drug spinoff from Hengrui Pharma, raising $625M and validating the 'NewCo' model for Chinese pharmaceutical companies.

Eli Lilly, Vertex Pharmaceuticals, and Intuitive Surgical possess durable competitive moats—patent protection and market dominance—supporting sustained earnings growth through the 2030s.

Target's 3.5% yield and 54-year dividend streak outweigh Conagra's risky 9.4% yield amid 42% stock decline and deteriorating fundamentals.

Beyond Meat pivots to protein drinks amid declining sales and delisting risk, targeting GLP-1 drug trends but facing competition from giants like PepsiCo's Muscle Milk.

Eli Lilly stock fell 2.5% after announcing a $7 billion acquisition of Kelonia Therapeutics for CAR-T cancer therapy, despite positive analyst rating.

Pfizer's experimental monthly GLP-1 injection threatens to disrupt the weight-loss market dominated by Novo Nordisk and Eli Lilly, potentially triggering price competition.

Eli Lilly received FDA approval for Foundayo weight-loss pill in April 2026. With 40%+ growth and premium valuation, stock needs only 20% gain to hit $1 trillion market cap.

$LLY surged 1,100% in ten years via GLP-1 drugs, but 39x P/E ratio and patent risks loom.

Eli Lilly reaches $1 trillion valuation while outperforming Novo Nordisk over three years, driven by superior weight-loss drug efficacy and robust pipeline strength.

Simply Good Foods ($SMPL) stock crashed 18% after Q2 earnings missed revenue forecasts by $17.86M. Guidance slashed to -7% to -10% decline amid intensifying competition and GLP-1 drug headwinds.

Eli Lilly's Mounjaro loses market share in India to cheaper GLP-1 generics; sales fell 16% in March. FDA approves Lilly's oral GLP-1 Foundayo.